Table 1 Baseline characteristics
CD n =466 | CP n =509 | |
|---|---|---|
n (%) | ||
Median age, years | 60.5 | 61.0 |
ECOG performance status a | ||
0 | 286 (61) | 317 (62) |
1 | 159 (34) | 164 (32) |
2 | 13 (3) | 15 (3) |
Primary disease site ovarian | 415 (89) | 451 (89) |
Papillary/serous histology | 334 (72) | 366 (72) |
Initial FIGO stage a | ||
I/II | 52 (11) | 59 (12) |
III/IV | 401 (86) | 427 (84) |
Number of previous therapy lines | ||
1 | 408 (88) | 421 (83) |
2 | 58 (12) | 87 (17) |
Prior taxane | 462 (99) | 500 (99) |
Median interval since prior therapy | ||
6–12 months | 162 (35) | 182 (36) |
>12 months | 304 (65) | 326 (64) |
Measurable disease | ||
Yes | 281 (60) | 321 (63) |
No | 185 (39) | 188 (37) |
Tumour size | ||
<5 cm | 377 (81) | 419 (82) |
⩾5 cm | 89 (19) | 90 (18) |
Number of sites of recurrence | ||
1 | 217 (47) | 245 (48) |
>1 | 249 (53) | 264 (52) |
